Phase I Study of the Combination of MLN9708 and Fulvestrant in Patients with Advanced Estrogen Receptor-Positive Breast Cancer
Participants in this study will have been diagnosed with advanced breast cancer that has
become worse while being treated with fulvestrant. Participants will have estrogen-receptor
positive disease, and have completed menopause.
There is information from research labs which suggests that drugs that work like MLN9708 help
kill breast cancer cells that have been treated with fulvestrant. The purpose of the study is
to determine the proper dose as well as the good and bad effects of MLN9708 when it is given
in combination with fulvestrant. The Investigators also want to learn more about how the drug
combination affects tumor cells.
The amount of MLN9708 participants receive will be determined by when they enter this study.
Three different doses will be given to different participants. The Investigators expect to
enroll a total of 12-18 people.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.